국내 제약기업의 R&D투자와 기업특성요인 간 관계 : 비모수적 접근
Relationship Between Research and Development Investment and Firm-specific Factors of Korean Pharmaceutical Firms: A Nonparametric Approach
1
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Objectives: Using data on 86 Korean pharmaceutical firms over a 5-year period from 2013 to 2017, this study empirically analyzes the relationship between research and development (R&D) investment and firm-specific factors. Methods: Investment variables are R&D expenditure and intensity. Variables for firm-specific factors include firm size, firm age, firm location, technological innovation, and export orientation. Nonparametric statistical methods are used to test the difference in R&D investment and groups are then classified according to the level of firm-specific factors for inter- or between-group comparison. Results: First, R&D intensity was related to firm size, firm age, and technological innovation. Second, R&D expenditure was related to firm size and technological innovation and this relationship was statistically significant. Conclusions: The results are expected to provide policy implications for R&D investment decisions and strategic choices made by managers as well as policy makers.
Abstract
Objectives: Using data on 86 Korean pharmaceutical firms over a 5-year period from 2013 to 2017, this study empirically analyzes the relationship between research and development (R&D) investment and firm-specific factors. Methods: Investment variables are R&D expenditure and intensity. Variables for firm-specific factors include firm size, firm age, firm location, technological innovation, and export orientation. Nonparametric statistical methods are used to test the difference in R&D investment and groups are then classified according to the level of firm-specific factors for inter- or between-group comparison. Results: First, R&D intensity was related to firm size, firm age, and technological innovation. Second, R&D expenditure was related to firm size and technological innovation and this relationship was statistically significant. Conclusions: The results are expected to provide policy implications for R&D investment decisions and strategic choices made by managers as well as policy makers.
참고문헌 (25)
- P. M. Romer, "The Origins of Endogenous Growth", Journal of Economic Perspective, 8(1), pp.3~22 (1994)
- N. L. Stokey, "R&D and Economic Growth", The Review of Economic Studies, 62(3), pp.469~489 (1995)
- G. Dosi, "Sources, Procedures and Microeconomic Effects of Innovation", Journal of Economic Literature, 26(3), pp.1120~1171 (1988)
- D. Shefer, "R&D, Firm Size and Innovation : An Empirical Analysis", Technovation, 25, pp.25~32 (2005)
- IFPMA, "The Pharmaceutical Industry and Global Health: Facts and Figures", 13~ (2017)
- EvaluatePharma, "World Preview 2016, Outlook to 2022", Evaluate Ltd, 28~ (2016)
- G. Bottazzi, "Innovation and Corporate Growth in the Evolution of the Drug Industry", International journal of industrial organization, 19, pp.1161~1187 (2001)
- A. Schuhmacher, "Models for Open Innovation in the Pharmaceutical Industry", Drug Discovery Today, 18(23-24), pp.1133~1137 (2013)
- KPBMA, "Pharmaceutical Industry Data Book", pp.10~11 (2019), Pharmaceutical Industry Data Book
- Survey of Research and Development in Korea, "KISTEP", 34~35 (2018)
- S. B. Graves, "Innovative Productivity and Returns to Scale in the Pharmaceutical Industry", Strategic Management Journal, 14(8), pp.593~605 (1993)
- 김동환, "제약기업 연구개발투자규모 결정요인", 보건경제와 정책연구, 16(2), pp.101~123 (2010), 한국보건경제정책학회
- B. Goldar, "R&D Intensity and Exports : A Study of Indian Pharmaceutical Firms", Innovation and Development, 3(2), pp.151~167 (2013)
- 사공진, "제약산업의 R&D 투자, 기업 규모 및 성과에 대한 연구: 슘페터 가설 검정과 신약 개발을 중심으로", 보건경제와 정책연구, 23(3), pp.37~62 (2017), 한국보건경제정책학회
- S. Tyagi, "Firm Level R&D Intensity : Evidence from Indian Drugs and Pharmaceutical Industry", Review of Managerial Science, 12(1), pp.167~202 (2018)
- Y. An, "Determinants of Technological Innovation : Panel Study of Medical and Pharmaceutical Industry", Science and Technology Policy, 2(2), pp.229~246 (2019)
- 이문재, "패널자료를 이용한 제약산업의 연구개발투자 결정요인분석: 외국인투자자와 기관투자가를 중심으로", 보건의료산업학회지, 9(3), pp.247~254 (2015), 보건의료산업학회
- K. Kushnir, "Micro, Small, and Medium Enterprises Around the World: How Many Are There, and What Affects the Count?", The World Bank, 2010, pp.1~9
- 김태기, "한국 수출기업과 내수기업의 총요소생산성 비교 분석", 한국경제연구, 33(1), pp.145~167 (2015), 한국경제연구학회
- 남상건, "Nonparametric statistical tests for the continuous data: the basic concept and the practical use", Korean Journal of Anesthesiology, 69(1), pp.8~14 (2016), 대한마취통증의학회[DOI]
- M. Abdelmoula, "Determination of R&D Investment in French Firms : A Two-part Hierarchical Model with Correlated Random Effects", Economics of Innovation and New Technology, 19(1), pp.53~70 (2010)
- D. B. Audretsch, "R&D Spillovers and the Geography of Innovation and Production", The American Economic Review, 86(3), pp.630~640 (1996)
- D. B. Audretsch, "Agglomeration and the Location of Innovative Activity", Oxford Review of Economic Policy, 14(2), pp.18~29 (1998)
- D. Shefer, "Local Milieu and Innovations : Some Empirical Results", The Annals of Regional Science, 32(1), pp.185~200 (1998)
- Regional Competency Analysis of Korea Biotechnology Industry, "KBERC", 8~11, pp.Bio-Economy Report, Issue 3 (2019)